1. Home
  2. In The News
  3. Momenta, BioFactura team up on biosimilars

Momenta, BioFactura team up on biosimilars

From From the BioPharmaDive.com
By Suzanne Elvidge 22SEP2016

Getting biosimilars right at the manufacturing stage is vitally important, as there must be no clinically meaningful differences between the follow-on biologic and its reference product. Even small changes to cell lines can lead to major changes in how a biologic behaves, including its safety, efficacy and ability to trigger immune reactions. Creating an alliance with a biomanufacturing company…

<Read Full Article>

September 22, 2016 In The News
About BioFactura

BioFactura (Frederick MD) develops and commercializes high-value biosimilars (i.e., follow-on biologics or generic biopharmaceuticals) using its patented StableFast Biomanufacturing Platform, the optimal system for bringing these drugs to market with faster, lower cost, superior-quality manufacture. For over 10 years, BioFactura has been advancing life-saving medicines from the research bench to the patient using its innovative drug development and manufacturing technologies. Current and past programs include biodefense drugs against smallpox and Ebola, novel medicines for cancer, and low-cost/high-quality biosimilars for autoimmune and infectious diseases.